| 2017 | | Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study | 서광욱 |
| 2002 | | Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. | 김명욱, 김효철, 이기범, 임호영, 조용관, 주희재, 최진혁 |
| 2013 | | Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. | 김영배, 윤지수, 이광, 한상욱, 허훈 |
| 2001 | | Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. | 김명욱, 김현수, 김효철, 남동기, 이기범, 임호영, 조용관, 주희재, 최진혁 |
| 2002 | | Is postoperative radiotherapy useful for the rectal carcinoma in the era of total mesorectal excision? | 서광욱, 임호영, 전미선 |
| 2013 | | Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. | 김도윤, 김영배, 서광욱, 오승엽 |
| 2014 | | Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. | 김도윤, 김영배, 서광욱, 오승엽, 이제희 |
| 2017 | | Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy | 김영배, 노오규, 서광욱, 오승엽 |
| 2019 | | Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer | 손상용, 이다근, 최경숙, 한상욱, 함인혜, 허훈 |
